Business
Promising Gelesis Data in Chronic Constipation
Promising Gelesis Data in Chronic Constipation.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 4828Z PureTech Health PLC 20 May 2019 \n\n20 May 2019\n \nPureTech Health plc\n \nPureTech Health Affiliate Gelesis Announces Promising Pilot Clinical Data From Prototype of GS500 In Development for Chronic Idiopathic Constipation\n \nInvestigational candidate developed by Gelesis demonstrated significant 16 hour reduction in colonic transit time in patients with chronic idiopathic constipation\n \nFirst clinical study of programme's efficacy in common condition that affects up to 25% of US population\n \nData presented at Digestive Disease Week further supports proprietary hydrogel platform's potential across a variety of chronic diseases of the gastrointestinal pathway\n \nPureTech Health plc (LSE:PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, is pleased to note that its affiliate Gelesis announced promising clinical data from a pilot study of its GS500 prototype (GS500/ CSP01), which is being explored as a potential treatment for chronic idiopathic constipation (CIC). The data demonstrated that GS500 provided a significant reduction in colonic transit time in patients with CIC, relative to placebo. The data package was presented by Gelesis research collaborators from Brigham and Women's Hospital and Massachusetts General Hospital at Digestive Disease Week 2019, the world's largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, held in San Diego, California.\nThe primary end-point of this randomised, double-blind study was the change in colonic transit time (CTT) from pre-treatment to post-treatment as measured by wireless motility capsules. Two populations were evaluated separately, 27 subjects with CIC and 13 subjects with irritable bowel syndrome with constipation (IBS-C). Patients were randomised into three treatment groups to receive 21 days of treatment with either GS500 (n=20), active control (modified cellulose, n=11) or placebo (n=9). Each subject's CTT was measured during the third week of treatment and compared to their baseline, collected during 7 days of pre-treatment. In the CIC population on treatment, colonic transit time was reduced by approximately 16 hours (~31%) com...